Metal Complex NCDs for Blood-Brain Barrier Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents for neurodegenerative diseases such as Alzheimer's, Parkinson's, and oxidative stress-related conditions are ineffective due to inability to cross the blood-brain barrier, and there is a need for novel agents that can effectively treat central nervous system disorders and gastrointestinal issues associated with these diseases.
Innovation Solution
Development of non-covalent derivatives (NCDs) of metal complexes, particularly copper and zinc, which act as ion chelators, enabling targeted delivery of bio-available metals to cells, thereby mediating antioxidant effects and treating conditions associated with oxidative stress and neurodegenerative disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If traditional therapeutic agents (vitamin E, vitamin C) are used, then they can be administered systemically, but they cannot cross the blood-brain barrier effectively
Solution Approach 1:
The patent uses metal complexes (copper, zinc, manganese) as intermediary carriers that can cross the blood-brain barrier through active transport mechanisms. These metals serve as mediators between systemic administration and CNS target sites, enabling therapeutic delivery where traditional antioxidants fail.
Solution Approach 2:
The invention changes the chemical parameters of the therapeutic agent by complexing antioxidants with metal ions. This transformation modifies the molecular properties (charge, size, lipophilicity) of the agent, enabling it to cross the blood-brain barrier while retaining antioxidant activity.
2Reliability
If metal complexes are used to cross the blood-brain barrier, then CNS delivery is improved, but specificity of metal delivery to target cells must be ensured
Solution Approach 1:
The patent employs ligands with specific chemical properties (carboxylic acid groups, nitrogen donors) that create locally optimized coordination environments. These ligands are designed to match the specific biochemical conditions of target cells, ensuring metals are delivered precisely where needed and released only at the intended destination.
Solution Approach 2:
The metal complex system incorporates feedback mechanisms where the ligand structure responds to cellular environments (pH, redox potential, metal ion concentrations). This allows the complex to remain stable during circulation but undergo controlled dissociation or activation upon reaching the target site, preventing off-target deposition.
3Object-affected harmful factors
If antioxidants are used to treat oxidative stress, then they can reduce ROS, but they are inadequately loaded with metal ions for effective enzyme function
Solution Approach 1:
The patent merges two functions into a single molecular entity: the antioxidant activity of ligands (vitamin C, vitamin E, polyphenols) and the metal ion binding capacity of chelating agents. This creates hybrid complexes that simultaneously provide radical scavenging and metal-dependent catalytic activities, eliminating the need for separate metal loading steps.
Solution Approach 2:
The invention creates composite metal complex structures combining organic antioxidant ligands with inorganic metal centers. These composite materials exhibit synergistic properties where the organic component provides antioxidant function and the metal center provides catalytic activity, achieving effective oxidative stress management.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The NCDs effectively deliver metals to cells, reducing oxidative stress, improving motor and cognitive functions, and alleviating gastrointestinal symptoms in neurodegenerative diseases, while also serving as diagnostic tools for copper and other divalent metals.
Implementation Method 1
non-covalent derivatives (NCDs) of metal complexes, particularly copper and zinc, which act as ion chelators, enabling targeted delivery of bio-available metals to cells
Data Source
AI summary
In one embodiment, the present application discloses compounds that are selective neuroactive agents for the treatment of diseases of the central nervous system (CNS). In one aspect, the neuroactive agents are NCDs of metal chelates, including complexes of iron, copper or zinc.